Medicine and Dentistry
Systematic Review
75%
COVID-19
50%
Placebo
48%
Randomized Controlled Trial
44%
Odds Ratio
35%
Randomized Clinical Trial
33%
Drug Effect
33%
Blocking Agent
33%
Interleukin 6
33%
Meta-Analysis
25%
Tocilizumab
25%
Sarilumab
18%
Health Care
16%
General Practitioner
16%
Adverse Event
9%
All Cause Mortality
6%
Health Expenditure
6%
Subgroup Analysis
5%
Experimental Drug
5%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
64%
Randomized Controlled Trial
33%
Blocking Agent
33%
Interleukin 6
33%
Tocilizumab
25%
Disease
18%
Sarilumab
18%
Randomized Clinical Trial
17%
Ischemic Heart Disease
16%
Valvular Heart Disease
16%
Population Study
16%
Cross-Sectional Study
16%
Atrial Fibrillation
16%
Long Term Survival
16%
Coronavirinae
16%
Congestive Heart Failure
16%
Adverse Event
9%
All Cause Mortality
6%
Therapeutic Effect
5%
Nursing and Health Professions
Systematic Review
100%
Clinical Guideline
50%
Confidence Interval
39%
Blocking Agent
33%
Interleukin 6
33%
Tocilizumab
30%
Sarilumab
22%
Disease
19%
Placebo
18%
Adverse Event
11%
All Cause Mortality
8%
Medline
5%
Siltuximab
5%
World Health Organization
5%
